Important histologic outcome predictors for patients with invasive ductal carcinoma of the breast

American Journal of Surgical Pathology

Volumn 35, Issue 10, 2011, Pages 1484-1497

  Hasebe, Takahiro ^a   Iwasaki, Motoki ^b   Akashi Tanaka, Sadako ^c   Hojo, Takashi ^c   Shibata, Tatsuhiro ^d   Kinoshita, Takayuki ^c   Tsuda, Hitoshi ^c  

^a Center for Cancer Control and Information Services   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

fibroblast; fibrotic focus; lymph node; lymph vessel; mitotic figure

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; FIBROSIS; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; PREDICTIVE VALUE; SURVIVAL RATE; TUMOR EMBOLISM; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; FIBROSIS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; YOUNG ADULT;

EID: 80053354376     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318224ca28     Document Type: Article

References (30)

1. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200-206 (Pubitemid 23046895)
2. Andersson Y, Frisell J, Sylvan M, et al. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol. 2010;28:2868-2873
3. Baak JP, Colpaert CG, van Diest PJ, et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in nodenegative invasive breast cancers. Eur J Cancer. 2005;41:2093-2101 (Pubitemid 41337951)
4. Baak JP, van Dieast PJ, Voorhorst F, et al. The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer. 2007;43:527-535 (Pubitemid 46177581)
5. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer. 1957;11:359-377
6. Colpaert C, Vermeulen PB, Jeuris W, et al. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol. 2001;193:442-449 (Pubitemid 32266812)
7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-4l0
8. Fernandes RCM, Bevilacqua JLB, Soares IC, et al. Coordinated expression ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology. 2009;55:346-352
9. Gabos Z, Thoms J, Ghosh S, et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 2010;124:187-194
10. Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol. 1993;11:1929-1935 (Pubitemid 23304618)
11. Harvey JM, Clark GM, Osborne K, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481 (Pubitemid 29220854)
12. Hasebe T, Tsuda H, Tsubono Y, et al. Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn J Cancer Res. 1998;88:590-599 (Pubitemid 27348496)
13. Hasebe T, Sasaki S, Imoto S, et al. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol. 2002;15:502-516 (Pubitemid 34521399)
14. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat. 1998;49:195-208 (Pubitemid 28416785)
15. Hasebe T, Sasaki S, Imoto S, et al. Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: a prospective study. Hum Pathol. 2004;35:298-308 (Pubitemid 38339603)
16. Hasebe T, Yamauchi C, Iwasaki M, et al. Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol. 2008;39:427-436 (Pubitemid 351193070)
17. Hasebe T, Okada N, Tamura N, et al. p53 expression in tumorstromal fibroblasts is closely associated with the outcome of patients with invasive ductal carcinoma. Cancer Sci. 2009;100:2101-2108
18. Hasebe T, Okada N, Iwasaki M, et al. Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast. Hum Pathol. 2010;41:706-715
19. Hasebe T, Iwasaki M, Akashi-Tanaka S, et al. Atypical tumorstromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol. 2011;35:325-336
20. Hasebe T, Iwasaki M, Akashi-Tanaka S, et al. Prognostic significance of mitotic figures in metastatic mammary ductal carcinoma to the lymph nodes. Hum Pathol. 2011 (In press)
21. Jatoi I, Hilsenbeck SG, Clark GM, et al. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17:2334-2340 (Pubitemid 29368231)
22. Lauria R, Perrone F, Carlomagno C, et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer. 1995;76:1772-1778
23. Maiorano E, Regan MM, Viale G, et al. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two international breast cancer study group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat. 2010;121:211-218
24. Marotti JD, Collins LC, Hu R, et al. Estrogen receptor-X expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2010;23:197-204
25. Miyashita M, Ishida T, Ishida K, et al. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch. 2010;458:65-72
26. Mohsin S, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545-1554 (Pubitemid 39627082)
27. Skaland I, van Diest PJ, Janssen EAM, et al. Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. Hum Pathol. 2008;39: 584-590
28. Sobin LH, Gospodarowicz MK, Wittekind Ch. International Union Against Cancer TNM classification of malignant tumours. In: Sobin LH, Gospodarowicz MK, Wittekind Ch. eds. 7th eds. Classification of Malignant Tumours. Geneva: Wiley-Liss; 2009:181-193
29. Weigand RA, Isenberg WM, Russo J, et al. Blood vessel invasion and axillary lymph node Involvement as prognostic indicators for human breast cancer. Cancer. 1982;50:962-969 (Pubitemid 12047133)
30. Wolff AC, Hammond ME, Schwartz JN, et al. American Scociety of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43 (Pubitemid 46174133)